A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration
Abstract We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/bc91a8dbe7224475a7ce9c259ddea49c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:bc91a8dbe7224475a7ce9c259ddea49c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:bc91a8dbe7224475a7ce9c259ddea49c2021-12-02T16:08:23ZA prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration10.1038/s41598-017-09632-02045-2322https://doaj.org/article/bc91a8dbe7224475a7ce9c259ddea49c2017-08-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-09632-0https://doaj.org/toc/2045-2322Abstract We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8,480,849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10−6 were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment.Kenji YamashiroKeisuke MoriShigeru HondaMariko KanoYasuo YanagiAkira ObanaYoichi SakuradaTaku SatoYoshimi NagaiTaiichi HikichiYasushi KataokaChikako HaraYasurou KoyamaHideki KoizumiMunemitsu YoshikawaMasahiro MiyakeIsao NakataTakashi TsuchihashiKuniko Horie-InoueWataru MatsumiyaMasashi OgasawaraRyo ObataSeigo YoneyamaHidetaka MatsumotoMasayuki OhnakaHirokuni KitameiKaori SayanagiSotaro OotoHiroshi TamuraAkio OishiSho KabasawaKazuhiro UeyamaAkiko MikiNaoshi KondoHiroaki BesshoMasaaki SaitoHidenori TakahashiXue TanKeiko AzumaWataru KikushimaRyo MukaiAkihiro OhiraFumi GomiKazunori MiyataKanji TakahashiShoji KishiHiroyuki IijimaTetsuju SekiryuTomohiro IidaTakuya AwataSatoshi InoueRyo YamadaFumihiko MatsudaAkitaka TsujikawaAkira NegiShin YoneyaTakeshi IwataNagahisa YoshimuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-8 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Kenji Yamashiro Keisuke Mori Shigeru Honda Mariko Kano Yasuo Yanagi Akira Obana Yoichi Sakurada Taku Sato Yoshimi Nagai Taiichi Hikichi Yasushi Kataoka Chikako Hara Yasurou Koyama Hideki Koizumi Munemitsu Yoshikawa Masahiro Miyake Isao Nakata Takashi Tsuchihashi Kuniko Horie-Inoue Wataru Matsumiya Masashi Ogasawara Ryo Obata Seigo Yoneyama Hidetaka Matsumoto Masayuki Ohnaka Hirokuni Kitamei Kaori Sayanagi Sotaro Ooto Hiroshi Tamura Akio Oishi Sho Kabasawa Kazuhiro Ueyama Akiko Miki Naoshi Kondo Hiroaki Bessho Masaaki Saito Hidenori Takahashi Xue Tan Keiko Azuma Wataru Kikushima Ryo Mukai Akihiro Ohira Fumi Gomi Kazunori Miyata Kanji Takahashi Shoji Kishi Hiroyuki Iijima Tetsuju Sekiryu Tomohiro Iida Takuya Awata Satoshi Inoue Ryo Yamada Fumihiko Matsuda Akitaka Tsujikawa Akira Negi Shin Yoneya Takeshi Iwata Nagahisa Yoshimura A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| description |
Abstract We conducted a genome-wide association study (GWAS) on the outcome of anti-VEGF treatment for exudative age-related macular degeneration (AMD) in a prospective cohort. Four hundred and sixty-one treatment-naïve AMD patients were recruited at 13 clinical centers and all patients were treated with 3 monthly injections of ranibizumab followed by pro re nata regimen treatment for one year. Genomic DNA was collected from all patients for a 2-stage GWAS on achieving dry macula after the initial treatment, the requirement for an additional treatment, and visual acuity changes during the 12-month observation period. In addition, we evaluated 9 single-nucleotide polymorphisms (SNPs) in 8 previously reported AMD-related genes for their associations with treatment outcome. The discovery stage with 256 patients evaluated 8,480,849 SNPs, but no SNPs showed genome-wide level significance in association with treatment outcomes. Although SNPs with P-values of <5 × 10−6 were evaluated in replication samples of 205 patients, no SNP was significantly associated with treatment outcomes. Among AMD-susceptibility genes, rs10490924 in ARMS2/HTRA1 was significantly associated with additional treatment requirement in the discovery stage (P = 0.0023), and pooled analysis with the replication stage further confirmed this association (P = 0.0013). ARMS2/HTRA1 polymorphism might be able to predict the frequency of injection after initial ranibizumab treatment. |
| format |
article |
| author |
Kenji Yamashiro Keisuke Mori Shigeru Honda Mariko Kano Yasuo Yanagi Akira Obana Yoichi Sakurada Taku Sato Yoshimi Nagai Taiichi Hikichi Yasushi Kataoka Chikako Hara Yasurou Koyama Hideki Koizumi Munemitsu Yoshikawa Masahiro Miyake Isao Nakata Takashi Tsuchihashi Kuniko Horie-Inoue Wataru Matsumiya Masashi Ogasawara Ryo Obata Seigo Yoneyama Hidetaka Matsumoto Masayuki Ohnaka Hirokuni Kitamei Kaori Sayanagi Sotaro Ooto Hiroshi Tamura Akio Oishi Sho Kabasawa Kazuhiro Ueyama Akiko Miki Naoshi Kondo Hiroaki Bessho Masaaki Saito Hidenori Takahashi Xue Tan Keiko Azuma Wataru Kikushima Ryo Mukai Akihiro Ohira Fumi Gomi Kazunori Miyata Kanji Takahashi Shoji Kishi Hiroyuki Iijima Tetsuju Sekiryu Tomohiro Iida Takuya Awata Satoshi Inoue Ryo Yamada Fumihiko Matsuda Akitaka Tsujikawa Akira Negi Shin Yoneya Takeshi Iwata Nagahisa Yoshimura |
| author_facet |
Kenji Yamashiro Keisuke Mori Shigeru Honda Mariko Kano Yasuo Yanagi Akira Obana Yoichi Sakurada Taku Sato Yoshimi Nagai Taiichi Hikichi Yasushi Kataoka Chikako Hara Yasurou Koyama Hideki Koizumi Munemitsu Yoshikawa Masahiro Miyake Isao Nakata Takashi Tsuchihashi Kuniko Horie-Inoue Wataru Matsumiya Masashi Ogasawara Ryo Obata Seigo Yoneyama Hidetaka Matsumoto Masayuki Ohnaka Hirokuni Kitamei Kaori Sayanagi Sotaro Ooto Hiroshi Tamura Akio Oishi Sho Kabasawa Kazuhiro Ueyama Akiko Miki Naoshi Kondo Hiroaki Bessho Masaaki Saito Hidenori Takahashi Xue Tan Keiko Azuma Wataru Kikushima Ryo Mukai Akihiro Ohira Fumi Gomi Kazunori Miyata Kanji Takahashi Shoji Kishi Hiroyuki Iijima Tetsuju Sekiryu Tomohiro Iida Takuya Awata Satoshi Inoue Ryo Yamada Fumihiko Matsuda Akitaka Tsujikawa Akira Negi Shin Yoneya Takeshi Iwata Nagahisa Yoshimura |
| author_sort |
Kenji Yamashiro |
| title |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_short |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_full |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_fullStr |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_full_unstemmed |
A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| title_sort |
prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration |
| publisher |
Nature Portfolio |
| publishDate |
2017 |
| url |
https://doaj.org/article/bc91a8dbe7224475a7ce9c259ddea49c |
| work_keys_str_mv |
AT kenjiyamashiro aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT keisukemori aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shigeruhonda aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT marikokano aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasuoyanagi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiraobana aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoichisakurada aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takusato aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshiminagai aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT taiichihikichi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasushikataoka aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT chikakohara aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasuroukoyama aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidekikoizumi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT munemitsuyoshikawa aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masahiromiyake aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT isaonakata aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takashitsuchihashi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kunikohorieinoue aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT watarumatsumiya aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masashiogasawara aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryoobata aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT seigoyoneyama aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidetakamatsumoto aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masayukiohnaka aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hirokunikitamei aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kaorisayanagi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sotaroooto aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroshitamura aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiooishi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shokabasawa aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kazuhiroueyama aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akikomiki aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT naoshikondo aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroakibessho aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masaakisaito aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidenoritakahashi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT xuetan aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT keikoazuma aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT watarukikushima aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryomukai aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akihiroohira aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT fumigomi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kazunorimiyata aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kanjitakahashi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shojikishi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroyukiiijima aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tetsujusekiryu aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tomohiroiida aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takuyaawata aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT satoshiinoue aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryoyamada aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT fumihikomatsuda aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akitakatsujikawa aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiranegi aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shinyoneya aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takeshiiwata aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nagahisayoshimura aprospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kenjiyamashiro prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT keisukemori prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shigeruhonda prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT marikokano prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasuoyanagi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiraobana prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoichisakurada prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takusato prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yoshiminagai prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT taiichihikichi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasushikataoka prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT chikakohara prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT yasuroukoyama prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidekikoizumi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT munemitsuyoshikawa prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masahiromiyake prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT isaonakata prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takashitsuchihashi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kunikohorieinoue prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT watarumatsumiya prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masashiogasawara prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryoobata prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT seigoyoneyama prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidetakamatsumoto prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masayukiohnaka prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hirokunikitamei prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kaorisayanagi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT sotaroooto prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroshitamura prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiooishi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shokabasawa prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kazuhiroueyama prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akikomiki prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT naoshikondo prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroakibessho prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT masaakisaito prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hidenoritakahashi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT xuetan prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT keikoazuma prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT watarukikushima prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryomukai prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akihiroohira prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT fumigomi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kazunorimiyata prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT kanjitakahashi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shojikishi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT hiroyukiiijima prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tetsujusekiryu prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT tomohiroiida prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takuyaawata prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT satoshiinoue prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT ryoyamada prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT fumihikomatsuda prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akitakatsujikawa prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT akiranegi prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT shinyoneya prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT takeshiiwata prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration AT nagahisayoshimura prospectivemulticenterstudyongenomewideassociationstoranibizumabtreatmentoutcomeforagerelatedmaculardegeneration |
| _version_ |
1718384555275059200 |